Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesHome administration of intravenous methylprednisolone for multiple sclerosis relapses: the experience of French multiple sclerosis networks
Multiple Sclerosis, 06/30/09
Creange A et al. – Safety data, pt satisfaction, and economic considerations support home-based treatment of multiple sclerosis (MS) relapses with intravenous methylprednisolone, provided strict pt selection criteria are observed and the process is coordinated and closely monitored by an MS network.
Methods- Report of a multi-center series of MS pts treated at home for a relapse with a 3-day course of intravenous (IV) methylprednisolone
- Home administration of intravenous methylprednisolone coordinated by 4 MS networks in France
- Relapsed MS pts referred by neurologists
- Treatment administered by local nurse
- Analysis of safety and efficiency of this approach
- Estimation of related cost savings
- Pt satisfaction questionnaire for all pts
- IV methylprednisolone at home for 807 pts
- Mean disease duration: 10.3 ± 7.9 yrs
- Treatment often prescribed by community-based neurologists
- Delay between prescription and treatment: 2.8 ± 0.5 days if treatment initiated at home vs 1.9 ± 3.0 days if treatment initiated in hospital (subsequent 2 injections always at home)
- Home treatment: well tolerated
- Serious side effects requiring hospital transfer: anxiety, thoracic oppression, and arrhythmia; all fully reversible
- Overall, 93.8% of pts satisfied with treatment approach; 98% wished to receive future treatment courses at home
- Overall cost savings of home-based treatment vs hospital-based treatment evaluated at EUR1,091,482
Today in Demyelinating Disorders...keeping you current
Receive free subspecialty "5-minute updates" via email
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial : The Lancet
The Lancet - Early Online Publication, 10/08/09
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
The Lancet Neurology, 10/16/09
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders
Clinical Neuropharmacology, 10/02/09
Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial
The Lancet, 10/13/09
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/29/09
Sponsor
Article Search
Sponsor